Search

Search Constraints

You searched for: Author/Creator Rutkowski, P.

Search Results

2. 107. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate. Issue 9 (September 2016)

3. 108. The analysis of outcomes of primary cutaneous melanoma located on hand or foot undergoing sentinel lymph node biopsy. Issue 9 (September 2016)

4. 115P Reflectance confocal microscopy: An in vivo method of visualization of NMSC under anti-PD-1 therapy in correlation to histological findings - Preliminary report. (December 2022)

5. 2BA The interval between primary melanoma excision and sentinel node biopsy (SNB) does not affect survival; regardless of SNB status - an EORTC Melanoma Group study. (September 2015)

6. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. (September 2015)

7. 3313 The next generation sequencing (NGS) analysis of selected genes and pathways in clinical stage III cutaneous melanoma. (September 2015)

8. 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). (September 2015)

9. 3348 Cell-free DNA V600E measurements during vemurafenib therapy of metastatic melanoma patients. (September 2015)

10. 3404 External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS). (September 2015)